The major histocompatibility complex class I (MHC-I) antigen presentation pathway is central to the adaptive immune response. In this process, intracellular proteins are degraded primarily by the ...
Oncolytic herpes simplex virus type I (HSV-1) vectors are promising therapeutic agents for cancer. Their efficacy depends on the extent of both intratumoral viral replication and induction of a host ...
Our core provides customized MHC/peptide tetramers for identification of antigen-specific T lymphocytes by flow cytometry. Tetramers and/or their derivatives are provided for research purposes only.
Many cancers evade immune rejection by suppressing major histocompatibility class I (MHC-I) antigen processing and presentation (AgPP). Such cancers do not respond to immune checkpoint inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback